GGrantIndex
← Leaderboards

Luisa Escobar Hoyos

Sloan-Kettering Inst Can Research

$5,863,708
Attributed
$5,863,708
Total exposure
4
Grants
4
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $2.2M · FY201825
$2.5M$1.9M$1.3M$625K$0
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$5,863,708 · 4

By mechanism

DP2$2,512,500 · 1
R01$2,406,506 · 1
R00$740,588 · 1
K99$204,114 · 1

Top collaborators

No co-investigators on record.

Most similar at Sloan-Kettering Inst Can Research

Same institution · by research overlap

Others in their field

Other Emerging Leaders on “Rna Splicing

Research focus

Rna SplicingResponseTumorGenetic TranscriptionMutationMalignant Neoplasm Of PancreasMutantProtein IsoformsPancreatic Cancer PatientsTp53 GeneNovel TherapeuticsOncoproteinsPancreatic Ductal AdenocarcinomaPathogenesisMolecular SubtypesKras2 GeneSmall Molecule InhibitorIn VitroIn VivoSignal TransductionMessenger RnaMolecularGain Of FunctionSpliceosomes

Grant awards (13)

Unleashing T-cell anti-tumor response through repair of altered RNA splicing and antigen mimicry recognition$1,005,000
DP2 · FY2025 · CA · contact PI
Understanding and targeting mutant splicing factors in pancreatic cancer$738,594
R01 · FY2025 · CA · contact PI
Understanding and targeting mutant splicing factors in pancreatic cancer$327,677
R01 · FY2025 · CA · contact PI
Understanding and targeting mutant splicing factors in pancreatic cancer$357,313
R01 · FY2024 · CA · contact PI
Understanding and targeting mutant splicing factors in pancreatic cancer$155,616
R01 · FY2024 · CA · contact PI
Understanding and targeting mutant splicing factors in pancreatic cancer$396,332
R01 · FY2023 · CA · contact PI
Unleashing T-cell anti-tumor response through repair of altered RNA splicing and antigen mimicry recognition$1,507,500
DP2 · FY2022 · CA · contact PI
Understanding and targeting mutant splicing factors in pancreatic cancer$430,974
R01 · FY2022 · CA · contact PI
Altered mRNA splicing dependent on mutant p53 identifies novel therapeutic vulnerability in pancreatic cancer$245,749
R00 · FY2022 · CA · contact PI
Altered mRNA splicing dependent on mutant p53 identifies novel therapeutic vulnerability in pancreatic cancer$245,839
R00 · FY2021 · CA · contact PI
Altered mRNA splicing dependent on mutant p53 identifies novel therapeutic vulnerability in pancreatic cancer$249,000
R00 · FY2020 · CA · contact PI
Altered mRNA splicing dependent on mutant p53 identifies novel therapeutic vulnerability in pancreatic cancer$102,057
K99 · FY2019 · CA · contact PI
Altered mRNA splicing dependent on mutant p53 identifies novel therapeutic vulnerability in pancreatic cancer$102,057
K99 · FY2018 · CA · contact PI